부산대학교 도서관

Thrombosis is the main complication in myeloproliferative neoplasms (MPN). A JAK2V617F mutation has been shown to be a risk factor for thrombosis. The implication of other risk factors alongside a mutation allele burden needs to be clarified (Trifa et al., 2018; Borowczyk et al., 2015). Our aim was to investigate the role of the JAK2 mutation allele burden in the risk of cardiovascular events (CVE) and/or venous thrombosis (VTE) in a cohort of patients with confirmed MPN, as well as in patients without confirmed MPN. We restrospectively included all consecutive patients who were positive for JAK2V617F seen by our unit between December 2008 and September 2016. Inclusion criteria were a positive test for the JAK2V617F mutation, with at least 1% allele burden, with or without confirmed MPN. We included 239 patients of median age 71 years [60–81], followed-up for a median of 82.8 months [41.08–146.88]. For JAK2V617F positive patients having an allele burden superior to 50% the cumulative incidence of VTE was significantly higher than for those with an allele burden inferior to 50% (HR 3.11 95% CI [1.10–8.76] p = 0.031). The cumulative incidence of VTE was also higher in patients with obesity (HR 4.58 95% CI [1.33–15.8] p = 0.016). There was no significant association between a JAK2V617F allele burden and arterial thrombosis (manifesting as CVE). Previous VTE was also associated with a higher cumulative incidence of recurrence during follow-up HR 3.22 95% CI [1.17–8.81] p = 0.0231. We show that a JAK2V617F allele burden is associated with risk of VTE but not with CVE. • Venous and arterial thromboses are the leading cause of mortality in myeloproliferative neoplasms. • JAK2V617F mutation is the most common driver of myeloproliferative neoplasms development. • Patients with an allele burden >50% have a significantly higher incidence of VTE. • There was no significant association between allele burden and arterial thrombosis. • JAK2V617F allelic burden could be considered as a risk factor for venous thrombosis. [ABSTRACT FROM AUTHOR]